These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 21617168

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Aα-Val360: a marker of neutrophil elastase and COPD disease activity.
    Carter RI, Ungurs MJ, Mumford RA, Stockley RA.
    Eur Respir J; 2013 Jan; 41(1):31-8. PubMed ID: 22523359
    [Abstract] [Full Text] [Related]

  • 3. The Relationship of the Fibrinogen Cleavage Biomarker Aα-Val360 With Disease Severity and Activity in α1-Antitrypsin Deficiency.
    Carter RI, Ungurs MJ, Pillai A, Mumford RA, Stockley RA.
    Chest; 2015 Aug; 148(2):382-388. PubMed ID: 25569856
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).
    Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA.
    Am J Respir Crit Care Med; 1999 Dec; 160(6):1968-75. PubMed ID: 10588615
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A specific proteinase 3 activity footprint in α1-antitrypsin deficiency.
    Newby PR, Crossley D, Crisford H, Stockley JA, Mumford RA, Carter RI, Bolton CE, Hopkinson NS, Mahadeva R, Steiner MC, Wilkinson TMA, Sapey E, Stockley RA.
    ERJ Open Res; 2019 Jul; 5(3):. PubMed ID: 31403052
    [Abstract] [Full Text] [Related]

  • 11. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial.
    Campos MA, Geraghty P, Holt G, Mendes E, Newby PR, Ma S, Luna-Diaz LV, Turino GM, Stockley RA.
    Am J Respir Crit Care Med; 2019 Aug 01; 200(3):318-326. PubMed ID: 30965011
    [Abstract] [Full Text] [Related]

  • 12. The role of augmentation therapy in alpha-1 antitrypsin deficiency.
    Kueppers F.
    Curr Med Res Opin; 2011 Mar 01; 27(3):579-88. PubMed ID: 21226542
    [Abstract] [Full Text] [Related]

  • 13. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency.
    Hubbard RC, Crystal RG.
    Am J Med; 1988 Jun 24; 84(6A):52-62. PubMed ID: 3289387
    [Abstract] [Full Text] [Related]

  • 14. Genetic and biochemical markers of obstructive lung disease in the general population.
    Dahl M.
    Clin Respir J; 2009 Apr 24; 3(2):121-2. PubMed ID: 20298391
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alpha-1-antitrypsin replacement therapy: current status.
    Abusriwil H, Stockley RA.
    Curr Opin Pulm Med; 2006 Mar 24; 12(2):125-31. PubMed ID: 16456382
    [Abstract] [Full Text] [Related]

  • 19. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
    Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG, RAPID Trial Study Group.
    Lancet; 2015 Jul 25; 386(9991):360-8. PubMed ID: 26026936
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.